drugset / Trial / NCT07603401

Expanded Access Program of Bitopertin For Participants With EPP or XLP

NCT07603401

Expanded access Available Disc Medicine, Inc

Summary

The goal of this expanded access program is to provide bitopertin to patients with EPP and XLP who have no satisfactory treatment options available in the US and to learn if bitopertin is safe to treat EPP and XLP.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject bitopertin Small molecule 60 mg Oral